Johnson & Johnson

YTD

ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.

CEO

Joaquin Duato

CEOJoaquin Duato

Employees

138,100

Employees138,100

Headquarters

New Brunswick, New Jersey

HeadquartersNew Brunswick, New Jersey

Founded

1887

Founded1887

Employees

138,100

Employees138,100

JNJ Key Statistics

Market cap

390.85B

Market cap390.85B

Price-Earnings ratio

28.03

Price-Earnings ratio28.03

Dividend yield

3.03%

Dividend yield3.03%

Average volume

8.30M

Average volume8.30M

High today

$163.51

High today$163.51

Low today

$159.12

Low today$159.12

Open price

$159.68

Open price$159.68

Volume

12.55M

Volume12.55M

52 Week high

$168.85

52 Week high$168.85

52 Week low

$140.68

52 Week low$140.68

JNJ News

TipRanks 17h

Hold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects

Needham analyst Ami Fadia has maintained their neutral stance on ITCI stock, giving a Hold rating on February 6. Discover the Best Stocks and Maximize Your Por...

Seeking Alpha 19h

JNJ met main goal in late-stage trial for ulcerative colitis treatment

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with moderately to severely active ulcerative col...

Seeking Alpha 21h

Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara

Teva Pharmaceutical (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) have launched their biosimilar targeting Johnson & Johnson’s (NYSE:JNJ) blockbuster arthritis therapy...

Analyst ratings

52%

of 23 ratings

Buy

52.2%

Hold

47.8%

Sell

More JNJ News

Seeking Alpha 7d

Johnson & Johnson to resume U.S. Varipulse cases after safety review

Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety conc...